Navigation Links
VYVANSE provided behavior, inattention and math test score improvements in children with ADHD
Date:10/29/2008

CHICAGO October 29, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a 13-hour analog classroom study in school-aged children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD). In this study, researchers found that VYVANSE controlled ADHD symptoms from the first time point measured (1.5 hours) through the last time point assessed (13 hours) post-dose. Findings from this analog classroom study were presented today at a national psychiatric meeting in Chicago.

"The study presented today is the first published data demonstrating improvements in attention and behavior with an oral ADHD stimulant treatment for up to 13 hours post-dose," said Ann C. Childress, MD, study investigator, president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas, and volunteer assistant professor of psychiatry at the University of Nevada School of Medicine in Las Vegas. "In this study, once-daily VYVANSE significantly improved attention and behavior at 1.5 hours after a morning dose of the medication and continued to do so for each time point measured throughout the 13-hour treatment day. These findings are significant because children with ADHD require symptom control that lasts throughout the school day as well as after-school hours."

This study confirms the results of a previous clinical trial in which VYVANSE demonstrated ADHD symptom control throughout a 12-hour treatment day. The adverse events in the 12-hour study for patients taking Vyvanse during the double-blind treatment period that were greater than or equal to 2 percent were insomnia, decreased appetite, and anorexia.

"This is encouraging news for physicians and patients seeking a long-acting ADHD treatment option as this study demonstrated symptom control during a 13-hour treatment day," said Mike Cola, President of Shire's Specialty Pharmaceuticals business. "This VYVANSE st
'/>"/>

Contact: Jacelyn Seng
212-601-8385
Porter Novelli
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
2. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
3. FDA approves additional dosage strengths of Vyvanse
4. Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
5. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
6. Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity
7. All Pets With Cancer in U.S. Provided Free Consultation
8. NABP Findings Underscore Dangers of Purchasing Prescription Medicine Online and From Foreign Sources
9. New National Medicaid Study Underscores Importance of Including State Relief in Stimulus Plan
10. Score Big With One-of-a-Kind Swarovski Encrusted SCRABBLE(R) Board
11. Local Experts Help Women Living and Working with Cancer Even the Score
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... classes. , Starting September 1st they are offering pre and postnatal ... and "Healthy Body, Healthy Baby." , More information can be found at 248-601-6683. ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Coast ... Saturday, September 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the ... the opportunity to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article published ... Reconstructive Surgery Global Open Journal that discusses the future of 3-D printing technology as ... the future, customized implants, prosthetics, and other 3-D printed tools could be used to ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... Program at Monmouth, was one of the first doctors in the area to ... this new approach have been impressive: faster recovery, decreased immediate and long-term pain, ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
Breaking Medicine News(10 mins):Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2
... Since antiquity, people have been fascinated with larger-than-life characters, ... Looking at the legions of fans mourning the loss ... a modern phenomenon. But from the gods on Olympus ... Sinatra in the 1950s to Brad and Angelina today, ...
... Continues as Growth of Company Exemplifies the Best in Retirement Living ... demand for senior housing will outpace supply in the coming years. Couple ... the future of the senior housing industry looks very different than it ... Aegis Living, a national leader in ...
... June 26 The Agency for Healthcare Research and Quality,s ... mixed reviews for the quality of care they provide. ... no state does well or poorly on all quality measures. ... Services is also releasing state-by-state reports on the health care ...
... deadlier than a heart attack, experts say, with chances for ... star Michael Jackson probably did not die on Thursday of ... sudden cardiac arrest, experts say. , It,s not yet clear ... Angeles home, but that assumption has been made by many ...
... , , Employers demonstrated commitment to making employee health ... 26 HealthFitness (NYSE Amex: FIT ) today ... as "2009 Best Employers for Healthy Lifestyles" by the National ... http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , , According to the ...
... therapy, researchers say , FRIDAY, June 26 (HealthDay News) ... are more likely to have a level of arterial ... blood pressure, a new study finds. , Arterial stiffness ... high blood pressure. , The study provides new insight ...
Cached Medicine News:Health News:The Psychology of Celebrity Worship 2Health News:The Psychology of Celebrity Worship 3Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 2Health News:Aegis Living Was Created To Place People First in Senior and Assisted Living Communities 3Health News:New Snapshots Show States Vary Widely in Providing Quality Health Care 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 2Health News:Jackson's Death Puts Spotlight on Sudden Cardiac Arrest 3Health News:Several HealthFitness Clients Earn National Recognition for Employee Health Initiatives 2
(Date:8/31/2015)... August 31, 2015 ... OTCQX: BLGTY) ("BioLight" or the "Company"), a firm ... in ophthalmology and cancer diagnostics, today announced that ... has identified several new genetic markers with high ... patients treated with bisphosphonate drugs and was able ...
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... a strategic collaboration focused on the development, manufacture ... pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s strength ... expertise in developing and manufacturing controlled substance APIs ... tech transfer processes into these facilities. The collaboration ...
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. 31, ... Eisai Co., Ltd., and Purdue Pharma L.P. announced today ... for the development and commercialization of Eisai,s clinical candidate ... entering Phase III clinical development for the treatment of ... agreement, Eisai and Purdue Pharma will share the costs ...
Breaking Medicine Technology:BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5
... 2011 SV Life Sciences ("SVLS") today announced the ... SVLS in early 2009 as Venture Partner. ... tremendous experience with large-scale medical technology businesses to our ... Managing Partner. "In doing so, Paul has underscored a ...
... BROOK, N.J., Jan. 6, 2011 The FDA,s nod to ... they have to address the problems of sexual dysfunction. "So ... of Semprae Laboratories, Inc. The announcement of the approval of ... Flibanserin. Dubbed the "pink pill," the female Viagra equivalent, many ...
Cached Medicine Technology:SV Life Sciences Promotes 30-Year MedTech Veteran Paul LaViolette to Partner 2SV Life Sciences Promotes 30-Year MedTech Veteran Paul LaViolette to Partner 3What About Us? The State of Women's Sexual Health in Question 2
The unique RF-1501 optical design provides exceptional sensitivity in an incredibly compact instrument....
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
FlexStationII offers the highest level of flexibility in developing functional cellular assays and analyzing real time kinetic data....
... Modulus™ is a multifunctional ... to give you utmost ... luminescence, and absorbance. Modulus ... fluorometer, dedicated luminometer, or ...
Medicine Products: